Eli Lilly and Company $LLY Position Lifted by Lighthouse Financial LLC

Lighthouse Financial LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 10.8% in the 3rd quarter, Holdings Channel reports. The firm owned 5,747 shares of the company’s stock after buying an additional 558 shares during the period. Eli Lilly and Company accounts for approximately 3.0% of Lighthouse Financial LLC’s investment portfolio, making the stock its 8th biggest holding. Lighthouse Financial LLC’s holdings in Eli Lilly and Company were worth $6,650,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Capital Investment Advisors LLC boosted its position in shares of Eli Lilly and Company by 51.3% during the third quarter. Capital Investment Advisors LLC now owns 44,851 shares of the company’s stock worth $51,896,000 after purchasing an additional 15,214 shares in the last quarter. Wedbush Securities Inc. increased its position in shares of Eli Lilly and Company by 3.4% in the 3rd quarter. Wedbush Securities Inc. now owns 19,230 shares of the company’s stock valued at $22,250,000 after buying an additional 627 shares in the last quarter. Vision Financial Markets LLC increased its position in shares of Eli Lilly and Company by 10.5% in the 3rd quarter. Vision Financial Markets LLC now owns 420 shares of the company’s stock valued at $486,000 after buying an additional 40 shares in the last quarter. Atala Financial Inc increased its position in shares of Eli Lilly and Company by 1.9% in the 3rd quarter. Atala Financial Inc now owns 547 shares of the company’s stock valued at $633,000 after buying an additional 10 shares in the last quarter. Finally, Fifth Third Wealth Advisors LLC raised its stake in Eli Lilly and Company by 3.4% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 25,916 shares of the company’s stock worth $29,987,000 after buying an additional 848 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Trading Up 0.5%

Shares of NYSE:LLY opened at $1,279.29 on Tuesday. Eli Lilly and Company has a 12 month low of $809.63 and a 12 month high of $1,321.21. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The company’s fifty day simple moving average is $1,187.35 and its 200 day simple moving average is $1,086.38. The firm has a market cap of $1.20 trillion, a price-to-earnings ratio of 42.93, a PEG ratio of 1.71 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating the consensus estimate of $6.40 by $1.98. The business had revenue of $22.97 billion for the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm’s revenue was up 47.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 33.22 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s payout ratio is 23.22%.

Insider Transactions at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares in the company, valued at $14,131,250. The trade was a 29.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock valued at $15,958,170 over the last three months. Company insiders own 0.14% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Morgan Stanley lifted their target price on Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Weiss Ratings raised Eli Lilly and Company from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 15th. UBS Group set a $1,376.00 price target on Eli Lilly and Company in a report on Friday, August 7th. Leerink Partners raised their price target on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 21st. Finally, Wells Fargo & Company lifted their price objective on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $1,320.25.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: A U.S. judge declined to block Eli Lilly’s advertising for its weight-loss drugs in a case brought by Novo Nordisk. The ruling supports Lilly’s ability to market its obesity treatments and represents a favorable development in the competitive GLP-1 market. US judge won’t block Eli Lilly ads for weight-loss drugs
• Positive Sentiment: New clinical data for investigational lung-cancer drug olomorasib showed durable first-line activity in KRAS G12C-mutated non-small-cell lung cancer, strengthening Lilly’s pipeline beyond its obesity and diabetes franchises. New data on Lilly’s investigational treatment olomorasib
• Positive Sentiment: Early Phase 1 results for Lilly’s investigational sofe-m plus bevacizumab regimen in ovarian cancer showed high response and disease-control rates without major new safety signals. Although preliminary, the data add potential long-term value to the oncology pipeline. Lilly reports strong Phase 1 ovarian cancer data
• Positive Sentiment: The board declared a quarterly dividend of $1.73 per share, payable December 10 to shareholders of record November 13. The announcement provides a modest signal of financial confidence, though the dividend is not likely to be the primary stock catalyst. Lilly declares fourth-quarter 2026 dividend
• Neutral Sentiment: Analysts have high expectations for the October 29 earnings report, with investors focused on demand for weight-loss drugs, prescription trends, manufacturing capacity and updated full-year guidance. A strong report could extend the rally, while any miss could prompt volatility. Wall Street has high expectations for Eli Lilly
• Negative Sentiment: Competition from Novo Nordisk and broader pricing, patent and market-access pressures remain risks. Analysts also caution that revenue could temporarily soften even as patient numbers grow, while Lilly’s elevated valuation leaves the stock sensitive to weaker-than-expected guidance. Why revenue could dip even as patients grow

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.